Biosino Bio-Technology and Science Incorporation (the “Company”) formally entered into a strategic cooperation agreement with Guangdong Xiaoshou Medical Technology Co., Ltd. (“Xiaoshou Medical”) on 11 February 2026 in Beijing. The agreement focuses on collaboration in primary healthcare, with the goal of promoting the downward extension of quality medical resources and strengthening service capabilities at primary healthcare institutions.
Under the agreement, the Company intends to make a strategic investment in Xiaoshou Medical to explore innovative development models in the primary healthcare market. The partnership will leverage the Company’s product strengths and research and development capabilities in in-vitro diagnostics (IVD) as well as Xiaoshou Medical’s nationwide primary healthcare channel network and digital platform. Both parties will promote the distribution of biochemical, immunological, and POCT products directly to local healthcare providers. They will also enhance data insights, research and development, and supply chain optimization, establishing a joint working group to develop customized products and “smart laboratory comprehensive solutions.”
The collaboration will integrate equipment, reagents, operations, and data resources, providing one-stop laboratory service solutions to regional medical alliances and chain clinics. Phased approaches will begin with strategic pilot projects and gradually move to large-scale implementation, exploring further industrial and capital-level collaboration.
Xiaoshou Medical is a primary healthcare digital service provider in the People’s Republic of China (PRC). Over years of development, it has formed partnerships with tens of thousands of primary healthcare institutions across various provinces, and it operates a nationwide channel network supported by an AI digital platform.
None of the planned initiatives constitute legally binding transactions at present, and the specific measures remain subject to further negotiation. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.